bioRxivCancer BiologyPreprint
The novel curcumin analogue AKT-100 targets both mutant p53 and STAT3 in gynecologic cancer cells
Geneva L. WilliamsiD, Lane E. Smith, Jamie L. Padilla, Alexander Goss, Daisy Belmares-Ortega, Xiangxiang WuiD, Jennifer Daw, Sumegha MitraiD, Prakash G. Jagtap, Josh K. Monts, Jun‐yong Choe, Kimberly Kay LeslieiD
Abstract
Loss of normal p53 tumor-suppressive activity is common in advanced cancers, where TP53 mutations produce either p53-null states or highly expressed missense proteins with gain of oncogenic function. Mutant p53 proteins not only lose wild type p53 pro-apoptotic and DNA repair functions but also acquire new activities, including constitutive STAT3 activation. We hypothesize that directly targeting missense mutant p53 instead of downstream pathways is advantageous. Curcumin analogues have been reported to bind mutant p53, motivating the development of AKT-100, a novel analogue designed to restore wild type p53 functionality. AKT-100 binds mutant p53 and STAT3, as shown by fluorescence quenching, and inhibits STAT3 Tyr705 phosphorylation in KLE and COV362 cells. This agent exhibits potent cytotoxicity in gynecological cancer cells with IC50 values ranging from 4 nm to 2.51 {micro}M, and demonstrates synergy with the PARP inhibitor olaparib and with chemotherapy by suppressing alternative DNA repair mechanisms associated with therapeutic resistance. RNA sequencing and immunoblotting confirms AKT-100 reactivates wild type p53 transcriptional profiles regulating cell cycle arrest (CDKN1A/p21, GADD45A), apoptosis (PMAIP1/Noxa, DR5), and inhibits DNA replication and repair. These findings support AKT-100 as a promising therapeutic agent with the dual capabilities of directly targeting oncogenic mutant p53 and constitutively active STAT3. HighlightsO_LIAKT-100 is a novel curcumin analogue that functions as a WT p53 reactivator. C_LIO_LIAKT-100 inhibits STAT3 phosphorylation at Tyrosine 705 in endometrial and ovarian cancer cells. C_LIO_LICell proliferation is inhibited in multiple ovarian and serous endometrial cancer cell lines with AKT-100 as a single agent. C_LIO_LIAKT-100 is synergistic with PARP inhibitor olaparib and chemotherapy drugs carboplatin and paclitaxel. C_LI Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=132 SRC="FIGDIR/small/680794v3_ufig1.gif" ALT="Figure 1"> View larger version (48K): org.highwire.dtl.DTLVardef@1fdb8a8org.highwire.dtl.DTLVardef@6648acorg.highwire.dtl.DTLVardef@12d301aorg.highwire.dtl.DTLVardef@1b1370f_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers
Mohammed Alruwaili, Yanqi Guo, … Andrei V. Bakin·bioRxiv·Nov 6, 2025
- Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer
Esther P. B. Rodman, Michael J. Emch, … John R. Hawse·npj Precision OncologyPeer-reviewed·Jul 11, 2025
- P53-independent restoration of p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
X. Tian, N. Ahsan, … W. El-Deiry·bioRxiv·Oct 20, 2020
- Basal p53 activity is differentially impacted by individual mutations, defining the immediate response to genotoxicity
Maria Jose de la Concha, Patricia Eror Barnes, … Alena Pance·bioRxiv·Sep 5, 2024
- Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex
J.-Y. Lang, X. Wang, … C. Qing·bioRxiv·Aug 12, 2020
- A p53-Phosphoinositide Signalosome Regulates Nuclear Akt Activation
M. Chen, S. Choi, … R. A. Anderson·bioRxiv·Sep 17, 2021